|
2
|
11
|
4g21B |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
2
|
10
|
4g1yB |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
2
|
10
|
4g1zB |
Structural basis for the accommodation of bis- and tris-aromatic derivatives in vitamin d nuclear receptor |
|
1
|
11
|
4fgyB |
Identification of a unique ppar ligand with an unexpected binding mode and antibetic activity |
|
96
|
355
|
3qm0A |
Crystal structure of rtt109-ac-coa complex |
|
3
|
12
|
3qt0C |
Revealing a steroid receptor ligand as a unique ppargamma agonist |
|
105
|
404
|
3q33A |
Structure of the rtt109-accoa/vps75 complex and implications for chaperone-mediated histone acetylation |
|
110
|
405
|
3q68C |
Structure of the vps75-rtt109 histone chaperone-lysine acetyltransferase complex (full-length proteins in space group p212121) |
|
113
|
432
|
3q66C |
Structure of the vps75-rtt109 histone chaperone-lysine acetyltransferase complex (full-length proteins in space group p6122) |
|
82
|
274
|
3qahA |
Crystal structure of apo-form human mof catalytic domain |
|
98
|
404
|
3q35A |
Structure of the rtt109-accoa/vps75 complex and implications for chaperone-mediated histone acetylation |
|
3
|
11
|
3p89B |
Fxr bound to a quinolinecarboxylic acid |
|
2
|
11
|
3p88B |
Fxr bound to isoquinolinecarboxylic acid |
|
39
|
114
|
3p1eA |
Crystal structure of the bromodomain of human crebbp in complex with dimethyl sulfoxide (dmso) |
|
40
|
115
|
3p1dA |
Crystal structure of the bromodomain of human crebbp in complex with n-methyl-2-pyrrolidone (nmp) |
|
1
|
10
|
3olsC |
Crystal structure of estrogen receptor beta ligand binding domain |
|
2
|
10
|
3omoC |
Fragment-based design of novel estrogen receptor ligands |
|
3
|
10
|
3okhB |
Crystal structure of human fxr in complex with 2-(4-chlorophenyl)-1-[(1s)-1-cyclohexyl-2-(cyclohexylamino)-2-oxoethyl]-1h-benzimidazole-6-carboxylic acid |
|
1
|
10
|
3ollC |
Crystal structure of phosphorylated estrogen receptor beta ligand binding domain |
|
38
|
119
|
3p1fA |
Crystal structure of the bromodomain of human crebbp in complex with a hydroquinazolin ligand |
|
2
|
12
|
3okiB |
Crystal structure of human fxr in complex with (2s)-2-[2-(4-chlorophenyl)-1h-benzimidazol-1-yl]-n,2-dicyclohexylethanamide |
|
3
|
13
|
3ommB |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-fluorobenzoic acid |
|
3
|
11
|
3olfB |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3-methylbenzoic acid |
|
2
|
10
|
3ompC |
Fragment-based design of novel estrogen receptor ligands |
|
3
|
12
|
3ookB |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)-3,5-difluorobenzoic acid |
|
39
|
115
|
3p1cA |
Crystal structure of the bromodomain of human crebbp in complex with acetylated lysine |
|
1
|
10
|
3omqC |
Fragment-based design of novel estrogen receptor ligands |
|
3
|
12
|
3oofB |
Crystal structure of human fxr in complex with 4-({(2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexylacetyl}amino)benzoic acid |
|
3
|
12
|
3omkB |
Crystal structure of human fxr in complex with (2s)-2-[2-(4-chlorophenyl)-5,6-difluoro-1h-benzimidazol-1-yl]-2-cyclohexyl-n-(2-methylphenyl)ethanamide |
|
2
|
11
|
3lmpC |
Crystal structure of the ppargamma-lbd complexed with a cercosporamide derivative modulator |
|
3
|
12
|
3l3xB |
Crystal structure of dht-bound androgen receptor in complex with the first motif of steroid receptor coactivator 3 |
|
3
|
12
|
3l3zB |
Crystal structure of dht-bound androgen receptor in complex with the third motif of steroid receptor coactivator 3 |
|
3
|
10
|
3kmrC |
Crystal structure of raralpha ligand binding domain in complex with an agonist ligand (am580) and a coactivator fragment |
|
40
|
109
|
3io2A |
Crystal structure of the taz2 domain of p300 |
|
4
|
15
|
3ipsC |
X-ray structure of benzisoxazole synthetic agonist bound to the lxr-alpha |
|
4
|
15
|
3ipqB |
X-ray structure of gw3965 synthetic agonist bound to the lxr-alpha |
|
5
|
15
|
3ipuC |
X-ray structure of benzisoxazole urea synthetic agonist bound to the lxr-alpha |
|
113
|
317
|
3hvlA |
Tethered pxr-lbd/src-1p complexed with sr-12813 |
|
43
|
114
|
3i3jA |
Crystal structure of the bromodomain of human ep300 |
|
2
|
11
|
3hc6B |
Fxr with src1 and gsk088 |
|
3
|
11
|
3hc5B |
Fxr with src1 and gsk826 |
|
37
|
107
|
3gg3A |
Crystal structure of the bromodomain of human pcaf |
|
2
|
10
|
3gytB |
Nuclear receptor daf-12 from parasitic nematode strongyloides stercoralis in complex with its physiological ligand dafachronic acid delta 4 |
|
0
|
11
|
3h0aB |
Crystal structure of peroxisome proliferator-activated receptor gamma (pparg) and retinoic acid receptor alpha (rxra) in complex with 9-cis retinoic acid, co-activator peptide, and a partial agonist |
|
2
|
10
|
3gyuB |
Nuclear receptor daf-12 from parasitic nematode strongyloides stercoralis in complex with its physiological ligand dafachronic acid delta 7 |
|
2
|
8
|
3g8iZ |
Aleglitazar, a new, potent, and balanced ppar alpha/gamma agonist for the treatment of type ii diabetes |
|
2
|
13
|
3fxvB |
Identification of an n-oxide pyridine gw4064 analogue as a potent fxr agonist |
|
2
|
10
|
3g9eB |
Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type ii diabetes |
|
3
|
12
|
3furH |
Crystal structure of pparg in complex with int131 |
|
2
|
8
|
3feiZ |
Design and biological evaluation of novel, balanced dual ppara/g agonists |
